Xiamen Amoytop Biotech Co., Ltd. (SHA:688278)

Market Cap	23.04B -27.6%
Revenue (ttm)	3.82B +29.7%
Net Income	1.01B +15.1%
EPS	2.47 +14.3%
Shares Out	408.19M
PE Ratio	22.88
Forward PE	18.05
Dividend	0.62 (1.06%)
Ex-Dividend Date	May 9, 2025

Volume	6,017,162
Average Volume	2,915,139
Open	58.22
Previous Close	58.25
Day's Range	55.66 - 58.49
52-Week Range	54.54 - 93.52
Beta	-0.13
RSI	29.59
Earnings Date	Apr 29, 2026

About Xiamen Amoytop Biotech

Xiamen Amoytop Biotech Co., Ltd. engages in research, development, production, and sale of recombinant protein drugs in China and internationally. It offers various drug products, including pegsomatropin injection, pegfilgrastim injection, molgramostim, filgrastim, and oprelvekin; active pharmaceutical ingredients (APIs); and reagents to treat viral hepatitis, malignant tumors, and immunotherapy. Xiamen Amoytop Biotech Co., Ltd. was founded in 1996 and is headquartered in Xiamen, China.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1996
• Employees: 3,644
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 688278

Financial Performance

In 2025, Xiamen Amoytop Biotech's revenue was 3.70 billion, an increase of 31.18% compared to the previous year's 2.82 billion. Earnings were 1.03 billion, an increase of 24.61%.